Regorafenib is suitable for advanced colorectal cancer patients who have previously received trifluridine/tipiracil plus bevacizumab

Regorafenib is a standard salvage line therapy used for advanced colorectal cancer (CRC). Recently, trifluridine/tipiracil (TFTD) plus bevacizumab also showed promising efficacy as a salvage line therapy for advanced CRC. However, the efficacy and safety of regorafenib for patients with advanced CRC...

Descripción completa

Detalles Bibliográficos
Autores principales: Matsumoto, Toshihiko, Ikoma, Tatsuki, Yamamura, Shogo, Miura, Kou, Tsuduki, Takao, Watanabe, Takanori, Nagai, Hiroki, Takatani, Masahiro, Yasui, Hisateru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918455/
https://www.ncbi.nlm.nih.gov/pubmed/36765099
http://dx.doi.org/10.1038/s41598-023-29706-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918455/
https://www.ncbi.nlm.nih.gov/pubmed/36765099
http://dx.doi.org/10.1038/s41598-023-29706-6

Ejemplares similares